Raphael Bosse is an Oncology physician affiliated with University of Florida. OpenAlex indexes 19 publications with 249 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1100 Goodlette Rd
Naples, FL 341025451
Telephone
239-434-0656Provider last certified this registry record 24 Mar 2026.
Industry payments
59 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202515 payments
- Janssen Biotech, Inc.Program year202514 payments
- PFIZER INC.Program year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
50.5%Parenteral Iron Replacement39.7%Iron sucrose100%Part B, office-administered≥15 patientsErythropoiesis-stimulating Agent10.7%Epoetin alfa100%Part B, office-administered≥31 patients+ 1 more class in this area
Musculoskeletal
25.4%RANK Ligand Inhibitor25.4%Denosumab100%Part B, office-administered≥70 patientsMetabolism & gastrointestinal
11.1%Substance P/Neurokinin-1 Receptor Antagonist7.9%Aprepitant100%Part B, office-administered≥11 patientsSerotonin-3 Receptor Antagonist3.1%Palonosetron hcl52%Ondansetron hydrochloride44%Ondansetron Odt4%Part D + Part B≥23 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Investigation of Complications Following Port Insertion in a Cancer Patient Population: A Retrospective Analysis
Clinical Medicine Insights Oncology
2019 - Ommaya Reservoir Related Complications: A Single Center Experience and Review of Current Literature
International Journal of Clinical Oncology and Cancer Research
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Dekosky, MD
University of Florida
Brian Hoh, MD
University of Florida
Frederic Kaye, MD
University of Florida
Kelly Foote, MD
University of Florida
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”